Latest Research in Precision Immunotherapy and Mutation Profiling

Top Research Topics in Precision Immunotherapy and Mutation Profiling

• Cancer Immunotherapy and Biomarkers — 61 papers
• Lung Cancer Treatments and Mutations — 48 papers
• Cancer Genomics and Diagnostics — 31 papers
• Glioma Diagnosis and Treatment — 27 papers
• Single-cell and spatial transcriptomics — 21 papers
• Cancer Cells and Metastasis — 15 papers
• HER2/EGFR in Cancer Research — 14 papers
• Breast Cancer Treatment Studies — 12 papers
• BRCA gene mutations in cancer — 10 papers
• MicroRNA in disease regulation — 10 papers

Highest-Cited Papers

1. Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer (1 citations)
2. Extensive and differential platinum chemotherapy mutagenesis in livers of children (1 citations)
3. Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study
4. Prognostic Value of FST and Relevance to Immune Infiltration in Head and Neck Squamous Cell Carcinoma
5. Tumor-associated calcium signal transducer 2 expression as a promising therapeutic target in esophageal squamous cell carcinoma: a combined the Cancer Genome Atlas and an institutional cohort
6. A systemic neuroendocrine immune axis in breast cancer revealed by MMD regularized cross tissue latent alignment across four independent cohorts
7. Lobular carcinoma as a spectrum: resolving the gray zone between morphology, E-cadherin, and CDH1
8. Combination of Immune Checkpoint Inhibitors With Vascular Endothelial Growth Factor–Targeted Agents in Advanced Gastric and Gastroesophageal Adenocarcinoma
9. Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells
10. Immunogenic cell death as a mechanism of synergy between sunitinib and 177Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors
11. Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcoma
12. Phase III Trials Test First-Line Options in Advanced NSCLC
13. Discovery of Potent and Selective VHL-Recruiting PROTAC Degraders Targeting EGFR with Improved Developability and Potent Anti-NSCLC Efficacy
14. Deciphering the co-occurrence of germline variants in tumour suppressor genes and viral DNA detection in breast cancer: A case-control study from Pakistan
15. Siglec–15 promotes a feed-forward loop between TNBC cells and macrophages via the NF-κB/DcR3/CCL18/STAT3 axis
16. Coordinated cellular programmes distinguish responses to neoadjuvant PD-L1 blockade and potentiate combinatorial immunotherapy in ESCC
17. Understanding CHEK2’s role in breast cancer by analyzing breast cancers with and without CHEK2-specific genomic profiles
18. The Tumour-Suppressive Role of Myosin Heavy Chain 9 (MYH9) in Oral Squamous Cell Carcinoma
19. Construction of an m5Cscore based on m5C modification patterns to predict prognosis and personalized treatment outcomes in breast cancer
20. Safety management of anti TROP2 ADCs in patients with breast cancer

Sub-Regions

• Cancer Genomics and Diagnostics — 192 papers
• Lung Cancer Treatments and Mutations — 97 papers
• Cancer Immunotherapy and Biomarkers — 81 papers
• Glioma Diagnosis and Treatment — 80 papers
• Ferroptosis and cancer prognosis — 52 papers
• MicroRNA in disease regulation — 47 papers